Sirolimus for the treatment of progressive kaposiform hemangioendothelioma: A multicenter retrospective study
- 26 May 2017
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 141 (4) , 848-855
Abstract
Kaposiform hemangioendothelioma (KHE) is an aggressive disease with high morbidity and mortality. The aim of this study was to retrospectively evaluate the efficacy and safety of sirolimus for the treatment of progressive KHE. A multicenter, retrospective cohort study was conducted in patients with progressive KHE treated with sirolimus. A total of 52 patients were analyzed. Thirty‐seven (71%) patients exhibited Kasabach‐Merritt phenomenon (KMP) and were significantly younger than the patients without KMP [95% confidence interval (CI), 14.39–41.61; p < 0.001]. Patients without KMP were all treated with sirolimus alone, whereas 21 KMP patients with severe symptoms received short‐term combination therapy with prednisolone. Overall, 96% and 98% of patients showed improved relief of notable symptoms and/or improved complications at 6 and 12 months after treatment, respectively. After sirolimus treatment, significant decreases in mean severity scores occurred at 6 months (95% CI, 2.23–2.54, p < 0.001) and 12 months (95% CI, 1.53–1.90, p < 0.001). Compared to KMP patients, patients without KMP showed a response that was similar to but less pronounced during the 12 months of treatment (95% CI, 40.87–53.80; p < 0.001). For subgroup analysis of KMP patients, there were no significant differences in tumor shrinkage between those treated with combination therapy and those receiving sirolimus alone (95% CI, 18.11–25.02; p > 0.05). No patients permanently discontinued treatment due to toxicity‐related events, and no drug‐related deaths occurred. Sirolimus was effective and safe for the treatment of progressive KHE. Sirolimus may be considered as a first‐line therapy or as part of a multidisciplinary approach for the treatment of KHE.Keywords
Funding Information
- National Natural Science Foundation of China (81401606, 81400862)
- Science and Technology Commission of Shanghai Municipality (15411961800)
This publication has 44 references indexed in Scilit:
- Treatment of kaposiform hemangioendothelioma and tufted angiomaInternational Journal of Cancer, 2016
- Clinical Outcomes for Systemic Corticosteroids Versus Vincristine in Treating Kaposiform Hemangioendothelioma and Tufted AngiomaMedicine, 2016
- Medical Management of Tumors Associated With Kasabach-Merritt PhenomenonJournal of Pediatric Hematology/Oncology, 2013
- Consensus-Derived Practice Standards Plan for Complicated Kaposiform HemangioendotheliomaThe Journal of Pediatrics, 2013
- Kaposiform Hemangioendothelioma: Atypical Features and Risks of Kasabach-Merritt Phenomenon in 107 ReferralsThe Journal of Pediatrics, 2013
- Kasabach-Merritt PhenomenonJournal of Pediatric Hematology/Oncology, 2009
- Kaposiform hemangioendotheliomaEuropean Journal of Internal Medicine, 2009
- Kasabach-Merritt Phenomenon: A Retrospective Study of Treatment with VincristineJournal of Pediatric Hematology/Oncology, 2002
- Thrombocytopenic Coagulopathy (Kasabach-Merritt Phenomenon) Is Associated with Kaposiform Hemangioendothelioma and Not with Common Infantile HemangiomaPlastic and Reconstructive Surgery, 1997
- Infants with Kasabach-Merritt syndrome do not have “true” hemangiomasThe Journal of Pediatrics, 1997